Cited by 1,709Antibiotic Resistance in BacteriaAntibiotics Pharmacokinetics and EfficacySynthesis of β-Lactam Compounds

The DOI matches its Crossref record; 462 of the 464 references it cites were found in a registry or an index.

Three Decades of β-Lactamase Inhibitors

Open access

Drawz, Sarah M., Bonomo, Robert A.·2010·Clinical Microbiology Reviews

Open this paper in CoChat — free account

Abstract

Since the introduction of penicillin, beta-lactam antibiotics have been the antimicrobial agents of choice. Unfortunately, the efficacy of these life-saving antibiotics is significantly threatened by bacterial beta-lactamases. beta-Lactamases are now responsible for resistance to penicillins, extended-spectrum cephalosporins, monobactams, and carbapenems. In order to overcome beta-lactamase-mediated resistance, beta-lactamase inhibitors (clavulanate, sulbactam, and tazobactam) were introduced into clinical practice. These inhibitors greatly enhance the efficacy of their partner beta-lactams (amoxicillin, ampicillin, piperacillin, and ticarcillin) in the treatment of serious Enterobacteriaceae and penicillin-resistant staphylococcal infections. However, selective pressure from excess antibiotic use accelerated the emergence of resistance to beta-lactam-beta-lactamase inhibitor combinations. Furthermore, the prevalence of clinically relevant beta-lactamases from other classes that are resistant to inhibition is rapidly increasing. There is an urgent need for effective inhibitors that can restore the activity of beta-lactams. Here, we review the catalytic mechanisms of each beta-lactamase class. We then discuss approaches for circumventing beta-lactamase-mediated resistance, including properties and characteristics of mechanism-based inactivators. We next highlight the mechanisms of action and salient clinical and microbiological features of beta-lactamase inhibitors. We also emphasize their therapeutic applications. We close by focusing on novel compounds and the chemical features of these agents that may contribute to a "second generation" of inhibitors. The goal for the next 3 decades will be to design inhibitors that will be effective for more than a single class of beta-lactamases.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Integrity signals

Registry

Crossref · 10.1128/cmr.00037-09

Cites

462 of 462 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Extended-Spectrum β-Lactamases: a Clinical Update
Paterson, D. L., & Bonomo, R. A. (2005) · Clinical Microbiology Reviews · doi:10.1128/cmr.18.4.657-686.2005 · Cited by 3,495
Self-citation
Extended-Spectrum β-Lactamases in the 21st Century: Characterization, Epidemiology, and Detection of This Important Resistance Threat
Bradford, P. A. (2001) · Clinical Microbiology Reviews · doi:10.1128/cmr.14.4.933-951.2001 · Cited by 2,646
Carbapenemases: the Versatile β-Lactamases
Queenan, A. M., & Bush, K. (2007) · Clinical Microbiology Reviews · doi:10.1128/cmr.00001-07 · Cited by 2,609
A functional classification scheme for beta-lactamases and its correlation with molecular structure
Bush, K., Jacoby, G. A., & Medeiros, A. A. (1995) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.39.6.1211 · Cited by 2,485
Updated Functional Classification of β-Lactamases
Bush, K., & Jacoby, G. A. (2010) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01009-09 · Cited by 2,367
Federal Funding for the Study of Antimicrobial Resistance in Nosocomial Pathogens: No ESKAPE
Rice, L. B. (2008) · The Journal of Infectious Diseases · doi:10.1086/533452 · Cited by 2,328
AmpC β-Lactamases
Jacoby, G. A. (2009) · Clinical Microbiology Reviews · doi:10.1128/cmr.00036-08 · Cited by 2,277
Extended-spectrum β-lactamase-producing Enterobacteriaceae: an emerging public-health concern
Pitout, J. D. D., & Laupland, K. B. (2008) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(08)70041-0 · Cited by 2,068
The real threat of Klebsiella pneumoniae carbapenemase-producing bacteria
Nordmann, P., Cuzon, G., & Naas, T. (2009) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(09)70054-4 · Cited by 1,619
Prevention of Drug Access to Bacterial Targets: Permeability Barriers and Active Efflux
Nikaido, H. (1994) · Science · doi:10.1126/science.8153625 · Cited by 1,542

Show all 464 references

Research works printed but not linked: 14

Danel, F., M. G. Page, and D. M. Livermore. 2007. Class D β-lactamases, p. 163-194. In R. A. Bonomo and M. E. Tolmasky (ed.), Enzyme-mediated resistance to antibiotics: mechanisms, dissemination, and prospects for inhibition. ASM Press, Washington, DC.
Abstr. 47th Intersci. Conf. Antimicrob. Agents Chemother. 2007
Dubus, A., P. Ledent, J. Lamotte-Brasseur, and J. M. Frere. 1996. The roles of residues Tyr150, Glu272, and His314 in class C β-lactamases. Proteins25:473-485.
Foulds, G., W. E. Barth, J. R. Bianchine, A. R. English, D. Girard, S. L. Hayes, M. O'Brien, and P. Somani. 1980. Pharmacokinetics of CP-45.899 and pro-drug CP-47.904 in animals and humans, p. 353-356. In J. D. Nelson and C. Grassi (ed.), Current chemotherapy and infectious disease. American Society for Microbiology, Washington DC.
Galleni, M., and J. M. Frere. 2007. Kinetics of β-lactamases and pencillin-binding proteins, p. 195-213. In R. A. Bonomo and M. E. Tolmasky (ed.), Enzyme-mediated resistance to antibiotics: mechanisms, dissemination, and prospects for inhibition. ASM Press, Washington, DC.
F1-310. Abstr. 47th Intersci. Conf. Antimicrob. Agents Chemother. 2007
F1-333a. Abstr. 47th Intersci. Conf. Antimicrob. Agents Chemother. 2007
Livermore, D. M., M. Akova, P. J. Wu, and Y. J. Yang. 1989. Clavulanate and β-lactamase induction. J. Antimicrob. Chemother.24(Suppl. B):23-33.
A1-006. Abstr. 49th Intersci. Conf. Antimicrob. Agents Chemother. 2009
Meroueh, S., J. Cha, and S. Mobashery. 2007. Inhibition of class A β-lactamases, p. 101-114. In R. A. Bonomo and M. E. Tolmasky (ed.), Enzyme-mediated resistance to antibiotics: mechanisms, dissemination, and prospects for inhibition. ASM Press, Washingtion, DC.
Page, M. G. 2007. Resistance mediated by penicllin-binding proteins, p. 81-99. In R. A. Bonomo and M. E. Tolmasky (ed.), Enzyme-mediated resistance to antibiotics: mechanisms, dissemination, and prospects for Inhibition. ASM Press, Washington, DC.
F1-311. Abstr. 47th Intersci. Conf. Antimicrob. Agents Chemother. 2007
F1-0882. Abstr. 47th Intersci. Conf. Antimicrob. Agents Chemother. 2007
Slocombe, B., A. S. Beale, R. J. Boon, K. E. Griffin, P. J. Masters, R. Sutherland, and A. R. White. 1984. Antibacterial activity in vitro and in vivo of amoxicillin in the presence of clavulanic acid, p. 29-49. InProgress and perspectives on β-lactamase inhibition: a review of Augmentin. Custom Communications: Postgraduate Medicine, New York, NY.

Sorted by citations

Items 401–500 of 1,001

Can Inhibitor-Resistant Substitutions in the Mycobacterium tuberculosis β-Lactamase BlaC Lead to Clavulanate Resistance?: a Biochemical Rationale for the Use of β-Lactam–β-Lactamase Inhibitor Combinations
Kurz, S. G., Wolff, K., Hazra, S., Bethel, C. R., Hujer, A. M., Smith, K. M., Xu, Y., Tremblay, L. W., Blanchard, J. S., Nguyen, L., et al. (2013) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01253-13 · Cited by 45
Self-citation
Structural Basis for Different Substrate Profiles of Two Closely Related Class D β-Lactamases and Their Inhibition by Halogens
Stojanoski, V., Chow, D., Fryszczyn, B. G., Hu, L., Nordmann, P., Poirel, L., Sankaran, B., Prasad, B. V. V., & Palzkill, T. G. (2015) · Biochemistry · doi:10.1021/acs.biochem.5b00298 · Cited by 47
NOTA analogue: A first dithiocarbamate inhibitor of metallo-β-lactamases
Zhang, E., Wang, M., Huang, S.-C., Xu, S.-M., Cui, D.-Y., Bo, Y.-L., Bai, P.-Y., Hua, Y., Xiao, C., & Qin, S. (2017) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2017.10.074 · Cited by 45
Semisynthetic Analogues of Anhydrotetracycline as Inhibitors of Tetracycline Destructase Enzymes
Markley, J. L., Fang, L., Gasparrini, A. J., Symister, C. T., Kumar, H., Tolia, N. H., Dantas, G. A., & Wencewicz, T. A. (2019) · ACS Infectious Diseases · doi:10.1021/acsinfecdis.8b00349 · Cited by 45
Clinical characteristics and risk factors of tigecycline-associated hypofibrinogenaemia in critically ill patients
Hu, J., Xiao, Y., Zheng, Y., Lai, Y., Fang, X., & Fang, Q. (2020) · European Journal of Clinical Pharmacology · doi:10.1007/s00228-020-02860-w · Cited by 44
Antimicrobial activity of a quinuclidine-based FtsZ inhibitor and its synergistic potential with β-lactam antibiotics
Chan, F., Sun, N., Leung, Y., & Wong, K. (2014) · The Journal of Antibiotics · doi:10.1038/ja.2014.140 · Cited by 44
The Structural Basis of Coenzyme A Recycling in a Bacterial Organelle
Erbilgin, O., Sutter, M., & Kerfeld, C. A. (2016) · PLoS Biology · doi:10.1371/journal.pbio.1002399 · Cited by 43
A translational pharmacokinetic/pharmacodynamic model to characterize bacterial kill in the presence of imipenem-relebactam
Bhagunde, P. R., Zhang, Z., Racine, F., Carr, D. M., Wu, J., Young, K., & Rizk, M. L. (2019) · International Journal of Infectious Diseases · doi:10.1016/j.ijid.2019.08.026 · Cited by 44
The ClpX chaperone controls autolytic splitting of Staphylococcus aureus daughter cells, but is bypassed by β-lactam antibiotics or inhibitors of WTA biosynthesis
Jensen, C., Bæk, K. T., Gallay, C., Thalsø-Madsen, I., Xu, L., Jousselin, A., Torrubia, F. R., Paulander, W., Pereira, A. R., Veening, J., et al. (2019) · PLoS Pathogens · doi:10.1371/journal.ppat.1008044 · Cited by 41
Designing Inhibitors of β-Lactamase Enzymes to Overcome Carbapenem Resistance in Gram-Negative Bacteria
Davies, D. T., & Everett, M. J. (2021) · Accounts of Chemical Research · doi:10.1021/acs.accounts.0c00863 · Cited by 44
Synthesis of γ-, δ-, and ε-Lactams by Asymmetric Transfer Hydrogenation of N-(tert-Butylsulfinyl)iminoesters
Guijarro, D., Pablo, Ó., & Yus, M. (2013) · The Journal of Organic Chemistry · doi:10.1021/jo400164y · Cited by 44
Biochemical exploration of β-lactamase inhibitors
Arer, V., & Kar, D. (2023) · Frontiers in Genetics · doi:10.3389/fgene.2022.1060736 · Cited by 43
GES-18, a New Carbapenem-Hydrolyzing GES-Type β-Lactamase from Pseudomonas aeruginosa That Contains Ile80 and Ser170 Residues
Bebrone, C., Bogaerts, P., Delbrück, H., Bennink, S., Kupper, M. B., de Castro, R. R., Glupczynski, Y., & Hoffmann, K. M. V. (2012) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01784-12 · Cited by 43
Peptide-conjugated phosphorodiamidate morpholino oligomer (PPMO) restores carbapenem susceptibility to NDM-1-positive pathogensin vitroandin vivo
Sully, E. K., Geller, B. L., Li, L., Moody, C. M., Bailey, S. M., Moore, A. L., Wong, M., Nordmann, P., Daly, S. M., Sturge, C. R., et al. (2016) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkw476 · Cited by 43
Exploring the potential of boronic acids as inhibitors of OXA‐24/40 β‐lactamase
Werner, J. P., Mitchell, J. M., Taracila, M. A., Bonomo, R. A., & Powers, R. A. (2016) · Protein Science · doi:10.1002/pro.3100 · Cited by 43
Self-citation
Single-Center Evaluation of the Pharmacokinetics of WCK 5222 (Cefepime-Zidebactam Combination) in Subjects with Renal Impairment
Preston, R. A., Mamikonyan, G., DeGraff, S., Chiou, J., Kemper, C. J., Xu, A. S., Mastim, M. A., Yeole, R. D., Chavan, R. P., Patel, A. M., et al. (2018) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01484-18 · Cited by 43
An escape from ESKAPE pathogens: A comprehensive review on current and emerging therapeutics against antibiotic resistance
Singh, A., Tanwar, M., Singh, T. P., Sharma, S., & Sharma, P. K. (2024) · International Journal of Biological Macromolecules · doi:10.1016/j.ijbiomac.2024.135253 · Cited by 42
Ceftolozane/Tazobactam: a new option in the treatment of complicated gram-negative infections.
Sorbera, M. A., Chung, E., Ho, C. W., & Marzella, N. (2014) · PubMed Central · Cited by 42
Inhibition of Aminoglycoside 6′- N -Acetyltransferase Type Ib by Zinc: Reversal of Amikacin Resistance in Acinetobacter baumannii and Escherichia coli by a Zinc Ionophore
Lin, D. L., Tran, T., Alam, J. Y., Herron, S. R., Ramirez, M. S., & Tolmasky, M. E. (2014) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00129-14 · Cited by 42
Long period fiber grating working in reflection mode as valuable biosensing platform for the detection of drug resistant bacteria
Quero, G., Zuppolini, S., Consales, M., Diodato, L., Vaiano, P., Venturelli, A., Santucci, M., Spyrakis, F., Costi, M. P., Giordano, M., et al. (2016) · Sensors and Actuators B Chemical · doi:10.1016/j.snb.2016.02.086 · Cited by 42
The Construction of Chiral Fused Azabicycles Using a Pd-Catalyzed Allylic Substitution Cascade and Asymmetric Desymmetrization Strategy
An, Q., Liu, D., Shen, J., Liu, Y., & Zhang, W. (2016) · Organic Letters · doi:10.1021/acs.orglett.6b03529 · Cited by 42
Activity of Meropenem-Vaborbactam in Mouse Models of Infection Due to KPC-Producing Carbapenem-Resistant Enterobacteriaceae
Sabet, M., Tarazi, Z., Nolan, T. G., Parkinson, J., Rubio-Aparicio, D., Lomovskaya, O., Dudley, M. N., & Griffith, D. C. (2017) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01446-17 · Cited by 42
Shewanella spp. infections in Gran Canaria, Spain: retrospective analysis of 31 cases and a literature review
Martín‐Rodríguez, A. J., Martín-Pujol, O., Artiles, F., Bolaños-Rivero, M., & Römling, U. (2017) · JMM Case Reports · doi:10.1099/jmmcr.0.005131 · Cited by 42
Synthesis of Avibactam Derivatives and Activity on β‐Lactamases and Peptidoglycan Biosynthesis Enzymes of Mycobacteria
Edoo, Z., Iannazzo, L., Compain, F., de la Sierra-Gallay, I. L., TILBEURGH, H. V., Fonvielle, M., Bouchet, F., Run, E. L., Mainardi, J., Arthur, M., et al. (2018) · Chemistry - A European Journal · doi:10.1002/chem.201800923 · Cited by 42
Molecular and computational approaches to understand resistance of New Delhi metallo β-lactamase variants (NDM-1, NDM-4, NDM-5, NDM-6, NDM-7)-producing strains against carbapenems
Ali, A., Gupta, D., Srivastava, G., Sharma, A. K., & Khan, A. U. (2018) · Journal of Biomolecular Structure and Dynamics · doi:10.1080/07391102.2018.1475261 · Cited by 42
Label-Free Photonic Crystal-Based β-Lactamase Biosensor for β-Lactam Antibiotic and β-Lactamase Inhibitor
Xiao, F., Li, G., Wu, Y., Chen, Q., Wu, Z., & Yu, R. (2016) · Analytical Chemistry · doi:10.1021/acs.analchem.6b02457 · Cited by 42
Recent strategies for inhibiting multidrug-resistant and β-lactamase producing bacteria: A review
Fatima, H., Goel, N., Sinha, R., & Khare, S. K. (2021) · Colloids and Surfaces B Biointerfaces · doi:10.1016/j.colsurfb.2021.111901 · Cited by 40
Metabolic profiling as a tool for prioritizing antimicrobial compounds
Wu, C., Choi, Y. H., & van Wezel, G. P. (2015) · Journal of Industrial Microbiology & Biotechnology · doi:10.1007/s10295-015-1666-x · Cited by 40
Combination of Pantothenamides with Vanin Inhibitors as a Novel Antibiotic Strategy against Gram-Positive Bacteria
Jansen, P. A. M., Hermkens, P. H. H., Zeeuwen, P. L. J. M., Botman, P. N. M., Blaauw, R. H., Burghout, P., van Galen, P. M., Mouton, J. W., Rutjes, F. P. J. T., & Schalkwijk, J. (2013) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00603-13 · Cited by 41
Identification of Cisplatin and Palladium(II) Complexes as Potent Metallo-β-lactamase Inhibitors for Targeting Carbapenem-Resistant Enterobacteriaceae
Chen, C., Sun, L.-Y., Gao, H., Kang, P.-W., Li, J., Zhen, J.-B., & Yang, K. (2020) · ACS Infectious Diseases · doi:10.1021/acsinfecdis.9b00385 · Cited by 41
A quantum mechanics/molecular mechanics study on the hydrolysis mechanism of New Delhi metallo-β-lactamase-1
Zhu, K., Lu, J., Liang, Z. T., Kong, X., Ye, F., Lu, J., Geng, H., Chen, Y., Zheng, M., Jiang, H., et al. (2013) · Journal of Computer-Aided Molecular Design · doi:10.1007/s10822-012-9630-6 · Cited by 41
Enzyme Inhibitors: The Best Strategy to Tackle Superbug NDM-1 and Its Variants
Li, X., Zhao, D., Li, W., Sun, J., & Zhang, X. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms23010197 · Cited by 40
Penicillin-binding protein (PBP) inhibitor development: A 10-year chemical perspective
Bertonha, A. F., Silva, C. C. D. L., Shirakawa, K. T., Trindade, D. M., & Dessen, A. (2023) · Experimental Biology and Medicine · doi:10.1177/15353702231208407 · Cited by 43
4,5-Disubstituted 6-Aryloxy-1,3-dihydrobenzo[c][1,2]oxaboroles Are Broad-Spectrum Serine β-Lactamase Inhibitors
McKinney, D. C., Zhou, F., Eyermann, C. J., Ferguson, A. D., Prince, D. B., Breen, J. N., GIACOBBE, R. A., Lahiri, S. D., & Verheijen, J. C. (2015) · ACS Infectious Diseases · doi:10.1021/acsinfecdis.5b00031 · Cited by 40
Exploring the Inhibition of CTX-M-9 by β-Lactamase Inhibitors and Carbapenems
Bethel, C. R., Taracila, M. A., Shyr, T., Thomson, J. M., Distler, A. M., Hujer, K. M., Hujer, A. M., Endimiani, A., Papp‐Wallace, K. M., Bonnet, R., et al. (2011) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00089-11 · Cited by 40
Self-citation
Structure-Based Design of Potent and Ligand-Efficient Inhibitors of CTX-M Class A β-Lactamase
Nichols, D. A., Jaishankar, P., Larson, W., Smith, E. W., Liu, G., Beyrouthy, R., Bonnet, R., Renslo, A. R., & Chen, Y. (2012) · Journal of Medicinal Chemistry · doi:10.1021/jm2014138 · Cited by 42
Crystal Structures of KPC-2 and SHV-1 β-Lactamases in Complex with the Boronic Acid Transition State Analog S02030
Nguyen, N. Q., Krishnan, N. P., Rojas, L. J., Prati, F., Caselli, E., Romagnoli, C., Bonomo, R. A., & van den Akker, F. (2016) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.02643-15 · Cited by 40
Self-citation
Reversible inactivation of a peptidoglycan transpeptidase by a β-lactam antibiotic mediated by β-lactam-ring recyclization in the enzyme active site
Edoo, Z., Arthur, M., & Hugonnet, J. (2017) · Scientific Reports · doi:10.1038/s41598-017-09341-8 · Cited by 38
Escape mutations circumvent a tradeoff between resistance to a beta-lactam and resistance to a beta-lactamase inhibitor
Russ, D., Glaser, F., Tamar, E. S., Yelin, I., Baym, M., Kelsic, E. D., Zampaloni, C., Haldimann, A., & Kishony, R. (2020) · Nature Communications · doi:10.1038/s41467-020-15666-2 · Cited by 43
Biochemical and Structural Analysis of Inhibitors Targeting the ADC-7 Cephalosporinase of Acinetobacter baumannii
Powers, R. A., Swanson, H. C., Taracila, M. A., Florek, N. W., Romagnoli, C., Caselli, E., Prati, F., Bonomo, R. A., & Wallar, B. J. (2014) · Biochemistry · doi:10.1021/bi500887n · Cited by 40
Self-citation
ESBL-producing Escherichia coli and Klebsiella pneumoniae at a tertiary care hospital in Saudi Arabia
Somily, A. M., Habib, H. A., Absar, M. M., Arshad, M. Z., Manneh, K., Alsubaie, S., Al-Hedaithy, M. A., Sayyed, S. B., Shakoor, Z. A., & Murray, T. S. (2014) · The Journal of Infection in Developing Countries · doi:10.3855/jidc.4292 · Cited by 40
GENETIC VARIATION FOR ANTIBIOTIC PERSISTENCE INESCHERICHIA COLI
Stewart, B., & Rozen, D. E. (2011) · Evolution · doi:10.1111/j.1558-5646.2011.01467.x · Cited by 40
Prevalence of Plasmid-Mediated Quinolone Resistance Genes among Extended-Spectrumβ-Lactamase-ProducingKlebsiella pneumoniaeHuman Isolates in Iran
Shams, E., Firoozeh, F., Moniri, R., & Zibaei, M. (2015) · Journal of Pathogens · doi:10.1155/2015/434391 · Cited by 39
Porin Loss Impacts the Host Inflammatory Response to Outer Membrane Vesicles of Klebsiella pneumoniae
Turner, K. L., Cahill, B. K., DiLello, S. K., Gutel, D., Brunson, D. N., Albertí, S., & Ellis, T. N. (2015) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01627-15 · Cited by 39
The structure of the metallo-β-lactamase VIM-2 in complex with a triazolylthioacetamide inhibitor
Christopeit, T., Yang, K., Yang, S.-K., & Leiros, H. S. (2016) · Acta Crystallographica Section F Structural Biology Communications · doi:10.1107/s2053230x16016113 · Cited by 39
Single‐run capillary electrophoresis method for the fast simultaneous determination of amoxicillin, clavulanate, and potassium
Marra, M. C., Cunha, R. R., Muñoz, R. A. A., Batista, A. D., & Richter, E. M. (2017) · Journal of Separation Science · doi:10.1002/jssc.201700478 · Cited by 39
Activity of the β-Lactamase Inhibitor LN-1-255 against Carbapenem-Hydrolyzing Class D β-Lactamases from Acinetobacter baumannii
Vázquez-Ucha, J. C., Maneiro, M., Martínez-Guitián, M., Buynak, J. D., Bethel, C. R., Bonomo, R. A., Bou, G., Poza, M., González‐Bello, C., & Beceiro, A. (2017) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01172-17 · Cited by 39
Self-citation
The impact of inoculum size on the activity of cefoperazone-sulbactam against multidrug resistant organisms
Chang, P., Chen, C., Lu, Y. C., Lai, C., Huang, H.-L., Chuang, Y.-C., & Tang, H.-J. (2017) · Journal of Microbiology Immunology and Infection · doi:10.1016/j.jmii.2017.08.026 · Cited by 39
Structure-Based Analysis of Boronic Acids as Inhibitors of Acinetobacter -Derived Cephalosporinase-7, a Unique Class C β-Lactamase
Bouza, A. A., Swanson, H. C., Smolen, K. A., VanDine, A. L., Taracila, M. A., Romagnoli, C., Caselli, E., Prati, F., Bonomo, R. A., Powers, R. A., et al. (2017) · ACS Infectious Diseases · doi:10.1021/acsinfecdis.7b00152 · Cited by 39
Self-citation
Lipid oligonucleotides as a new strategy for tackling the antibiotic resistance
Kauss, T., Arpin, C., Bientz, L., Nguyen, P. V., Vialet, B., Benizri, S., & Barthélémy, P. (2020) · Scientific Reports · doi:10.1038/s41598-020-58047-x · Cited by 39
The hydrolytic water molecule of Class A β-lactamase relies on the acyl-enzyme intermediate ES* for proper coordination and catalysis
He, Y., Lei, J., Pan, X., Huang, X., & Zhao, Y. (2020) · Scientific Reports · doi:10.1038/s41598-020-66431-w · Cited by 39
Piperacillin-Tazobactam in Intensive Care Units: A Review of Population Pharmacokinetic Analyses
El‐Haffaf, I., Caissy, J.-A., & Marsot, A. (2021) · Clinical Pharmacokinetics · doi:10.1007/s40262-021-01013-1 · Cited by 38
Occurrence and detection of AmpC β-lactamases among Enterobacteriaceae isolates from patients at Ain Shams University Hospital
Elhady, S. A., & Adel, L. A. (2015) · Egyptian Journal of Medical Human Genetics · doi:10.1016/j.ejmhg.2015.03.001 · Cited by 38
Unique Fluorescent Imaging Probe for Bacterial Surface Localization and Resistant Enzyme Imaging
Chan, H. L., Lyu, L., Aw, J., Zhang, W., Li, J., Yang, H., Hayashi, H., Chiba, S., & Xing, B. (2018) · ACS Chemical Biology · doi:10.1021/acschembio.8b00172 · Cited by 38
When One Drug Is Not Enough
Brennan-Krohn, T., & Kirby, J. E. (2019) · Clinics in Laboratory Medicine · doi:10.1016/j.cll.2019.04.002 · Cited by 38
Co-delivery of ampicillin and β-lactamase inhibitor by selenium nanocomposite to achieve synergistic anti-infective efficiency through overcoming multidrug resistance
Wang, Z., Zhang, P., Ding, X., Wang, J., Sun, Y., Yin, C., Wang, W., Fan, C., & Sun, D. (2021) · Chemical Engineering Journal · doi:10.1016/j.cej.2021.128908 · Cited by 38
Biotechnological and industrial applications of Streptomyces metabolites
Khushboo, Kumar, P., Dubey, K. K., Usmani, Z., Sharma, M., & Gupta, V. K. (2021) · Biofuels Bioproducts and Biorefining · doi:10.1002/bbb.2294 · Cited by 38
Antibiotikaresistenzen gezielt überwinden
Chellat, M. F., Raguž, L., & Riedl, R. (2016) · Angewandte Chemie · doi:10.1002/ange.201506818 · Cited by 37
An Overview of Extended Spectrum Beta Lactamases and Metallo Beta Lactamases
Nagshetty, K., Mayegowda, S. B., Patil, S. A., Shivannavar, C. T., & Manjula, N. G. (2021) · Advances in Microbiology · doi:10.4236/aim.2021.111004 · Cited by 37
Antibacterial properties and atomic resolution X-ray complex crystal structure of a ruthenocene conjugated β-lactam antibiotic
Lewandowski, E. M., Skiba, J., Torelli, N. J., Rajnisz, A., Solecka, J., Kowalski, K., & Chen, Y. (2015) · Chemical Communications · doi:10.1039/c5cc00904a · Cited by 37
Ceftolozane/Tazobactam
Sucher, A. J., Chahine, E. B., Cogan, P. S., & Fete, M. G. (2015) · Annals of Pharmacotherapy · doi:10.1177/1060028015593293 · Cited by 37
Prevalence and antimicrobial susceptibility patterns of uropathogenic E. coli among people in Zakho, Iraq
Polse, R. F., Yousif, S., & Assafi, M. (2016) · International Journal of Research in Medical Sciences · doi:10.18203/2320-6012.ijrms20160813 · Cited by 37
Antimicrobial Adjuvants Drug Discovery, the Challenge of Avoid the Resistance and Recover the Susceptibility of Multidrug-Resistant Strains
Bueno, J. (2016) · Journal of Microbial & Biochemical Technology · doi:10.4172/1948-5948.1000281 · Cited by 37
Piperacillin–tazobactam as alternative to carbapenems for ICU patients
Pilmis, B., Jullien, V., Tabah, A., Zahar, J., & Brun‐Buisson, C. (2017) · Annals of Intensive Care · doi:10.1186/s13613-017-0334-x · Cited by 41
Total Syntheses of Bulgecins A, B, and C and Their Bactericidal Potentiation of the β-Lactam Antibiotics
Tomoshige, S., Dik, D. A., Akabane‐Nakata, M., Madukoma, C. S., Fisher, J. F., Shrout, J. D., & Mobashery, S. (2018) · ACS Infectious Diseases · doi:10.1021/acsinfecdis.8b00105 · Cited by 37
Discovery of potential inhibitors against New Delhi metallo-β-lactamase-1 from natural compounds: in silico-based methods
Salari-Jazi, A., Mahnam, K., Sadeghi, P., Damavandi, M. S., & Faghri, J. (2021) · Scientific Reports · doi:10.1038/s41598-021-82009-6 · Cited by 37
1,3‐Diazepine: A privileged scaffold in medicinal chemistry
Malki, Y., Martínez, J., & Masurier, N. (2021) · Medicinal Research Reviews · doi:10.1002/med.21795 · Cited by 37
Enhancing the drug sensitivity of antibiotics on drug-resistant bacteria via the photothermal effect of FeTGNPs
Zhang, Y., Wang, D., Liu, F., Shu, S., Zhang, H., Li, W., Li, Y., & Tian, H. (2021) · Journal of Controlled Release · doi:10.1016/j.jconrel.2021.11.018 · Cited by 37
Twelve Positions in a β-Lactamase That Can Expand Its Substrate Spectrum with a Single Amino Acid Substitution
Yi, H., Cho, K.-H., Cho, Y. S., Kim, K., Nierman, W. C., & Kim, H. S. (2012) · PLoS ONE · doi:10.1371/journal.pone.0037585 · Cited by 37
Epidemiology and resistance features of Acinetobacter baumannii isolates from the ward environment and patients in the burn ICU of a Chinese hospital
Gong, Y., Shen, X., Huang, G., Zhang, C., Luo, X., Yin, S., Wang, J., Hu, F., Peng, Y., & Li, M. (2016) · The Journal of Microbiology · doi:10.1007/s12275-016-6146-0 · Cited by 37
Penicillin-Binding Proteins, β-Lactamases, and β-Lactamase Inhibitors in β-Lactam-Producing Actinobacteria: Self-Resistance Mechanisms
Martin, J. F., Álvarez-Álvarez, R., & Liras, P. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23105662 · Cited by 40
Simultaneous detection and comparative pharmacokinetics of amoxicillin, clavulanic acid and prednisolone in cows’ milk by UPLC–MS/MS
Liu, Y., Zhu, K., Wang, J., Huang, X., Wang, G., Li, C., Cao, J., & Ding, S. (2015) · Journal of Chromatography B · doi:10.1016/j.jchromb.2015.11.031 · Cited by 36
Inhibiting the β-Lactamase of Mycobacterium tuberculosis (Mtb) with Novel Boronic Acid Transition-State Inhibitors (BATSIs)
Kurz, S. G., Hazra, S., Bethel, C. R., Romagnoli, C., Caselli, E., Prati, F., Blanchard, J. S., & Bonomo, R. A. (2015) · ACS Infectious Diseases · doi:10.1021/acsinfecdis.5b00003 · Cited by 36
Self-citation
Evaluation of different pretreatment protocols to detect accurately clinical carbapenemase-producing Enterobacteriaceae by MALDI-TOF
Monteferrante, C. G., Sultan, S., ten Kate, M. T., Dekker, L. J. M., Sparbier, K., Peer, M., Kostzrewa, M., Luider, T. M., Goessens, W. H. F., & Burgers, P. C. (2016) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkw208 · Cited by 36
γ-Carbon Activation through N-Heterocyclic Carbene/Brønsted Acids Cooperative Catalysis: A Highly Enantioselective Route to δ-Lactams
Xiao, Y., Wang, J., Xia, W., Shu, S., Jiao, S., Zhou, Y., & Liu, H. (2015) · Organic Letters · doi:10.1021/acs.orglett.5b01827 · Cited by 36
A focused fragment library targeting the antibiotic resistance enzyme - Oxacillinase-48: Synthesis, structural evaluation and inhibitor design
Akhter, S., Lund, B. A., Ismael, A., Langer, M. K., Isaksson, J. M., Christopeit, T., Leiros, H. S., & Bayer, A. (2017) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2017.12.085 · Cited by 36
Detection of Antimicrobial Susceptibility and Integrons Among Extended-spectrum β-lactamase Producing Uropathogenic Escherichia coli Isolates in Southwestern Iran
Ebrahim‐Saraie, H. S., Nezhad, N. Z., Heidari, H., Motamedifar, A., & Motamedifar, M. (2018) · Oman Medical Journal · doi:10.5001/omj.2018.40 · Cited by 35
Appropriate composites of cefoperazone–sulbactam against multidrug-resistant organisms
Lai, C., Chen, C., Lu, Y.-C., Lin, T.-P., Chuang, Y.-C., & Tang, H.-J. (2018) · Infection and Drug Resistance · doi:10.2147/idr.s175257 · Cited by 36
Mutation of kvrA Causes OmpK35 and OmpK36 Porin Downregulation and Reduced Meropenem-Vaborbactam Susceptibility in KPC-Producing Klebsiella pneumoniae
Dulyayangkul, P., Ismah, W. A. K. W. N., Douglas, E. J. A., & Avison, M. B. (2020) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.02208-19 · Cited by 36
Mechanistic Investigations of Metallo‐β‐lactamase Inhibitors: Strong Zinc Binding Is Not Required for Potent Enzyme Inhibition**
Wade, N., Tehrani, K. H. M. E., Brüchle, N. C., van Haren, M. J., Mashayekhi, V., & Martin, N. I. (2021) · ChemMedChem · doi:10.1002/cmdc.202100042 · Cited by 36
Light-triggerable and pH/lipase-responsive release of antibiotics and β-lactamase inhibitors from host-guest self-assembled micelles to combat biofilms and resistant bacteria
Chen, M., Qiu, B., Zhang, Z., Xie, S., Liu, Y., Xia, T., & Li, X. (2021) · Chemical Engineering Journal · doi:10.1016/j.cej.2021.130330 · Cited by 36
Drug Repurposing Approaches towards Defeating Multidrug-Resistant Gram-Negative Pathogens: Novel Polymyxin/Non-Antibiotic Combinations
Koh, A. J. J., Hussein, M. H., Rao, G. G., Li, J., & Velkov, T. (2022) · Pathogens · doi:10.3390/pathogens11121420 · Cited by 38
Network Models of TEM β-Lactamase Mutations Coevolving under Antibiotic Selection Show Modular Structure and Anticipate Evolutionary Trajectories
Guthrie, V. B., Allen, J. M., Camps, M., & Karchin, R. (2011) · PLoS Computational Biology · doi:10.1371/journal.pcbi.1002184 · Cited by 36
Animals living in polluted environments are potential source of antimicrobials against infectious agents
Lee, S., Siddiqui, R., & Khan, N. A. (2012) · Pathogens and Global Health · doi:10.1179/2047773212y.0000000033 · Cited by 36
Synthesis and Biological Activity of Highly Cationic Dendrimer Antibiotics
VanKoten, H. W., Dlakic, W. M., Engel, R. R., & Cloninger, M. J. (2016) · Molecular Pharmaceutics · doi:10.1021/acs.molpharmaceut.6b00628 · Cited by 37
Novel non-β-lactam inhibitor of β-lactamase TEM-171 based on acylated phenoxyaniline
Grigorenko, V. G., Andreeva, I. P., Rubtsova, M. Y., Le‐Deygen, I. M., Antipin, R. L., Majouga, A. G., Egorov, A. M., Beshnova, D. A., Kallio, J., Hackenberg, C., et al. (2016) · Biochimie · doi:10.1016/j.biochi.2016.10.011 · Cited by 36
Hydrolysis of clavulanate by Mycobacterium tuberculosis β-lactamase BlaC harboring a canonical SDN motif
Soroka, D., Li de la Sierra-Gallay, I., Dubée, V., Triboulet, S., van Tilbeurgh, H., Compain, F., Ballell, L., Barros, D., Mainardi, J.-L., Hugonnet, J.-E., et al. (2015) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00598-15 · Cited by 36
Structural Basis and Binding Kinetics of Vaborbactam in Class A β-Lactamase Inhibition
Pemberton, O. A., Tsivkovski, R., Totrov, M. M., Lomovskaya, O., & Chen, Y. (2020) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00398-20 · Cited by 38
Analysis of the Functional Contributions of Asn233 in Metallo-β-Lactamase IMP-1
Brown, N. G., Banks, L. D., Huang, W., Vongpunsawad, S., & Palzkill, T. G. (2011) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00340-11 · Cited by 35
Role of SCCmec type in resistance to the synergistic activity of oxacillin and cefoxitin in MRSA
Reichmann, N. T., & Pinho, M. G. (2017) · Scientific Reports · doi:10.1038/s41598-017-06329-2 · Cited by 35
Bactericidal potentials of silver and gold nanoparticles stabilized with cefixime: a strategy against antibiotic-resistant bacteria
Ali, S., Perveen, S., Shah, M. R., Zareef, M., Arslan, M., Basheer, S., Ullah, S., & Ali, M. (2020) · Journal of Nanoparticle Research · doi:10.1007/s11051-020-04939-y · Cited by 35
Novel Cephalosporin Conjugates Display Potent and Selective Inhibition of Imipenemase-Type Metallo-β-Lactamases
Tehrani, K. H. M. E., Wade, N., Mashayekhi, V., Brüchle, N. C., Jespers, W., Voskuil, K., Pesce, D., van Haren, M. J., van Westen, G. J. P., & Martin, N. I. (2021) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.1c00362 · Cited by 35
Engineering antibiotic production and overcoming bacterial resistance
Planson, A., Carbonell, P., Grigoras, I., & Faulon, J. (2011) · Biotechnology Journal · doi:10.1002/biot.201100085 · Cited by 36
Bio‐Responsive Sliver Peroxide‐Nanocarrier Serves as Broad‐Spectrum Metallo‐β‐lactamase Inhibitor for Combating Severe Pneumonia
Li, H., Duan, S., Li, L., Zhao, G., Li, W., Zhang, B., Ma, Y., Wu, M. X., Mao, Y., & Lu, M. (2023) · Advanced Materials · doi:10.1002/adma.202310532 · Cited by 34
Metallo-β-lactamase inhibitors: A continuing challenge for combating antibiotic resistance
Kang, S., Kim, D., & Lee, B. (2024) · Biophysical Chemistry · doi:10.1016/j.bpc.2024.107228 · Cited by 36
Understanding the Burden and Management of Urinary Tract Infections in Women
Baimakhanova, B. B., САДАНОВ, А. К., Trenozhnikova, L. P., Balgimbaeva, A. S., Baimakhanova, G. B., Orasymbet, S., Tleubekova, D., Amangeldi, A., Жаиковна, Т. З., Nurgaliyeva, Z. Z., et al. (2025) · Diseases · doi:10.3390/diseases13020059 · Cited by 45
Active-Site Protonation States in an Acyl-Enzyme Intermediate of a Class A β-Lactamase with a Monobactam Substrate
Vandavasi, V. G., Langan, P. S., Weiss, K. L., Parks, J. M., Cooper, J. B., Ginell, S. L., & Coates, L. (2016) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01636-16 · Cited by 34
Probing the Binding Affinity by Jarzynski’s Nonequilibrium Binding Free Energy and Rupture Time
Truong, D. T., & Li, M. S. (2018) · The Journal of Physical Chemistry B · doi:10.1021/acs.jpcb.8b02137 · Cited by 33
What's new in the treatment of multidrug-resistant gram-negative infections?
Mo, Y., Lorenzo, M. P., Farghaly, S., Kaur, K., & Housman, S. T. (2018) · Diagnostic Microbiology and Infectious Disease · doi:10.1016/j.diagmicrobio.2018.08.007 · Cited by 34
Optimal Piperacillin-Tazobactam Dosing Strategies against Extended-Spectrum-β-Lactamase-Producing Enterobacteriaceae
Abodakpi, H., Chang, K., Gao, S., Díaz, A. M. S., Cantón, R., & Tam, V. H. (2018) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01906-18 · Cited by 34

Authors: Drawz, S. M., & Bonomo, R. A.
Affiliations: Departments of Pathology
United States Department of Veterans Affairs (US)
Corresponding author: Bonomo, Robert A.
ORCID: Bonomo, Robert A.
Venue: Clinical Microbiology Reviews
Publisher: American Society for Microbiology
Published: 2010-01
Volume: 23
Issue: 1
Pages: 160-201
ISSN: 0893-8512 (ISSN-L)
1098-6618
DOI: 10.1128/cmr.00037-09
PMC: PMC2806661
OpenAlex: W1895007034
Cited by: 1,709
References: 464
Citations by year: 2026: 83 · 2025: 100 · 2024: 87 · 2023: 86 · 2022: 106 · 2021: 126 · 2020: 151 · 2019: 130 · 2018: 131 · 2017: 119 · 2016: 120 · 2015: 108 · 2014: 93 · 2013: 88 · 2012: 81
FWCI: 4.26
Type: journal article
Language: en
Open access: green
www.ncbi.nlm.nih.gov
Licence: journals.asm.org/non-commercial-tdm-license (tdm)
Locations: Clinical Microbiology Reviews (publishedVersion)
PubMed Central (publishedVersion)
PubMed (publishedVersion)
Funders: U.S. Public Health Service (1R01A1063517-01)
National Institute of General Medical Sciences (T32GM007250, T32GM07250)
Topics: Health Sciences › Medicine › Microbiology (medical) › Antibiotic Resistance in Bacteria
Health Sciences › Medicine › Pharmacology (medical) › Antibiotics Pharmacokinetics and Efficacy
Physical Sciences › Chemistry › Organic Chemistry › Synthesis of β-Lactam Compounds
Keywords: beta-lactamase inhibitors, beta-lactamase, beta-lactam resistance, clavulanic acid, sulbactam, tazobactam, mechanism-based inactivators, carbapenemase inhibitors, extended-spectrum cephalosporin resistance, Enterobacteriaceae, penicillin-resistant staphylococci
MeSH terms: Bacteria, Bacterial Infections, Bacterial Proteins, beta-Lactamases, Enzyme Inhibitors, Humans, beta-Lactam Resistance, beta-Lactamase Inhibitors

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Three Decades of β-Lactamase Inhibitors

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Self-check

Citations

Cites

Cited by

Related

Metadata

Record

About these checks